Germany’s Drug‑Price Move and the U. S. Push for Fair Share

The United States spends a huge portion of the money that fuels new medicines, from cancer drugs to treatments for rare diseases. Because American companies invest most of the research and development money, they earn a lot of the profits that cover these costs. European governments often negotiate low prices for medicines once they hit the market. This keeps drugs cheap for their citizens but means those countries pay far less than their share of the research costs. President Trump has tried to change this pattern. After issuing an executive order on drug pricing, his administration reached deals with drug makers that could save the U. S. about $529 billion over ten years, according to White House economists. Other nations have started to listen too; the United Kingdom agreed last year to pay 25 % more for new drugs in exchange for easing Trump’s tariffs. Germany, however, is taking the opposite path. Its new bill would let the country pay even less for cutting‑edge drugs, a move that critics say lets Germany benefit from American innovation without paying enough to support it. This is part of a broader debate about how much the U. S. should shoulder costs for things like defense and healthcare while allies reap benefits.The same issue shows up in NATO spending. For years, the U. S. financed a lot of military support for Europe, which allowed European governments to focus on domestic priorities. Trump argued that this was unsustainable and pushed Germany to contribute more. The drug‑price debate mirrors that dynamic: Europe’s cheap medicine costs raise prices for Americans, who then shoulder a larger share of the innovation budget. With rising fiscal pressure and growing competition from China, it is worth questioning whether the current global system places too much of a burden on America. Trump’s investigations into European manufacturing and trade practices already aim to balance the scales, and expanding them to cover pharmaceutical pricing could encourage fairer sharing of research costs. If Europe wants continued access to the world’s best medicines, it needs to invest more in the science that creates them. Sharing the financial responsibility would strengthen alliances and reduce costs for all parties involved.